Effect of Fenofibrate on Neonatal Hyperbilirubinemia: A Systematic Review and Meta-analysis

Document Type : Review Article


1 Students Research Committee, School of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran

2 Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

3 Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran


Background: Jaundice is one of the most common neonatal complications. Therefore, promptly diagnosing and treating it is vital. This study aimed to determine the effect of Fenofibrate and phototherapy compared to the phototherapy alone on total serum bilirubin (TSB) at 24 and 48 h (primary outcome) and side effects (secondary outcome).
Methods: English (Cochrane Library, Web of Science, Medline, CINAHL, PsycINFO, PubMed, and Google Scholar) and Persian (SID and Magiran) databases were searched using verified keywords (MeSH library) without time constraint. The risk of bias was assessed using the Cochrane Handbook. RevMan software (version 5.3) was used for meta-analysis and the mean difference was calculated as effect size. In heterogeneous cases, the random effect was reported instead of the fixed one. 
Results: The total number of studies found in all databases was 5482. Six articles were included in the present study. The results of the meta-analysis showed no statistically significant difference in TSB levels within 24 (Mean difference: -5.56; 95% Confidence Interval (95% CI): 4.53 to -16.05; P = 0.27) and 48 h (-4.77; 2.57 to -12.10; P= 0.20) between Fenofibrate with phototherapy group and the phototherapy alone group. No side effects have been reported in included studies.
Conclusion: Although the results of the five studies showed the significant effect of Fenofibrate as adjuvant therapy on reducing TSB level, the meta-analysis failed to show the same result in the study groups. It is recommended to perform more trials following all principles of randomized controlled trials to find an effective treatment for hyperbilirubinemia.


  1. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001; 344)8):
  2. Venna IC. Nelson textbook of pediatrics. Indian J Pediatr. 2003; 70:892.
  3. Scrafford CG, Mullany LC, Katz J, Khatry SK, LeClerq SC, Darmstadt GL, et al. Incidence of and risk factors for neonatal jaundice among newborns in southern Nepal. Trop Med Int Health. 2013; 18(11):1317-28.
  4. Maisels MJ, Kring E. The contribution of hemolysis to early jaundice in normal newborns. J Pediatr. 2006; 118(1):276-9.
  5. Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG, Ryan KJ. Epidemiology of neonatal hyperbilirubinemia. Pediatrics. 1985; 75(4):770-4.
  6. Watchko JF. Neonatal indirect hyperbilirubinemia and kernicterus. Avery's diseases of the Newborn. New York: Elsevier; 2018. P. 1198-218.
  7. Brumbaugh D, Mack C. Conjugated hyperbilirubinemia in children. Pediatr Rev. 2012; 33(7):291-302.
  8. Jaundice N. Clinical guidelines. Spanish: National Collaborating Centre for Women and Child Health; 2010.
  9. Kramer LI. Advancement of dermal icterus in the jaundiced newborn. Am J Dis Child. 1969; 118(3):454-8.

10. Rennie J, Burman-Roy S, Murphy MS. Neonatal jaundice: summary of NICE guidance. BMJ. 2010; 340:c2409.

11. Piazza A, Stoll B. The fetus and the neonatal infant-digestive system disorders (Kernicterus). Nelson text book of pediatrics. Philadelphia: WB Saunders Company; 2018.

12. Deshmukh J, Deshmukh M, Patole S. Probiotics for the management of neonatal hyperbilirubinemia: a systematic review of randomized controlled trials. J Matern Fetal Neonatal Med. 2019; 32(1):154-63.

13. Kumar B, Agarwal PK, Chorishi A, Dhaneria M. Fenofibrate: a novel approach in treating uncomplicated neonatal hyperbilirubinemia. Peoples J Sci Res. 2012; 5:5-8.

14. Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr. 2002; 140(4):

15. Tarsilla M. Cochrane handbook for systematic reviews of interventions. J Multidisciplinary Evaluat. 2008; 6(14):142-8.

16. Anantha Narayana Gowda BL, Viswanathakumar HM, Yamuna BN, Arun Daniel J. Efficacy of oral fenofibrate in the management of unconjugated hyperbilirubinemia in neonates. Int J Recent Trends Sci Technol. 2014; 13(2):253-5.

17. Al-Asy HM, El-Sharkawy HM, Mabrouk MM, Hamad MR. Effect of fenofibrate on indirect neonatal hyperbilirubinemia. J Clin Neonatol. 2015; 4(2):82.

18. Ahmadpour-kacho M, Zahed Pasha Y, Moghadamnia AA, Khafri S, Vafaeinezhad M. The effect of oral fenofibrate on serum bilirubin level in term neonates with hyperbilirubinemia: a randomized clinical trail. Int J Pediatr. 2018; 6(10):8317-27.

19. Dabour SA, Ismael YM, Assar EH, Allam MM. Role of fenofibrate in management of unconjugated hyperbilirubinemia in neonates. Int J Adv Res (Indore). 2016; 4:12.

20. Chaudhary G, Chaudhary V, Chaurasiya, O, Chandrakant V, Kumar V. Oral fenofibrate in neonatal hyperbilirubinemia: A randomized controlled trial. Indian J Child Health. 2017; 3(1):54-8.

21. Muchowski KE. Evaluation and treatment of neonatal hyperbilirubinemia. Am Family Physician. 2014; 89(11):873-8.

22. Dennery PA. Pharmacological interventions for the treatment of neonatal jaundice. Semin Neonatol. 2002; 7(2):111-9.

23. Yang LP, Keating GM. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. Am J Cardiovasc Drugs. 2009; 9(6):401-9.

24. Balfour JA, McTavish D, Heel RC. Fenofi
brate. a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990; 40(2):260-90.

25. Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in management of dyslipidemia. Drugs.1997; 54(4):615-33.

26. Chapman MJ. Pharmacology of fenofibrate. Am J Med. 1987; 83(5B):21-5.

27. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002; 18(5):269-76.

28. Bethesda M. Fenofibrate. Maryland: American Society of Health-System Pharmacists; 2019.